The role of cytoreductive nephrectomy and systemic therapy in the management of tumour thrombus in patients with metastatic renal cell carcinoma.

"Competing interests There are no conflicts of interest pertaining to the contents of this manuscript. Other relationships are detailed: Dr. SS plays an advisory role for Astellas Pharma, Astrazeneca, Bayer, Bristol Mayers Squibb, Immunomedics, Janssen, Merck, Pfizer, Roche, Sanofi and Seattle Genetics. Dr. PC received honoraria from Abbvie, AstraZeneca and Boston Scientific, research funding from Abbvie and does consulting for Tersera and Verity Pharmaceuticals. Dr. RJH received honoraria from Abbvie, Astellas Pharma, Bayer and Janssen, research funding from Bayer and Janssen and travel/accommodation/expenses from Janssen. Dr. ARH does consulting for AstraZeneca, BMS, Eisai, GSK, Merck and Novartis. He has received research funding from Astellas Pharma, Astrazeneca, BionTech, Boehringer Ingelheim, BMS, GSK, Janssen, Karyopharm therapeutics, Merck, Neoleukin therapeutics, Pfizer/EMD Serono and Roche. Other authors have no relationships to disclose."

"Funding Open Access funding enabled and organized by CAUL and its Member Institutions."